Jula Inrig, Executive Vice President, Head of Research & Development & Chief Medical Officer, on September 15, 2026, sold 44,674 shares in Travere Therapeutics (TVTX) for $2,785,021. Following the ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...

Travere Therapeutics share news ...

Ligand Pharmaceuticals is rated a Hold, preferring entry after a pullback, given valuation risks and concentration concerns.

This is my thirteenth Ligand article, following my most recent 06/2026's "Ligand Pharma: Expect Bright And Exciting Future ...

Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Anthropic IPO will be delayed until November, the WSJ reported. OpenAI forecast massive negative cash flow, the FT ...

Officer PETER HEERMA intends to sell 172.72K shares of its common stock on Sep 16, with a total market value of approximately ...

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...